Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001062993-22-001182
Filing Date
2022-01-18
Accepted
2022-01-18 16:45:19
Documents
63
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 20-F/A form20fa.htm   iXBRL 20-F/A 1188605
7 GRAPHIC form20faxz004.jpg GRAPHIC 14594
  Complete submission text file 0001062993-22-001182.txt   6350702

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT drug-20210930.xsd EX-101.SCH 97360
3 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT drug-20210930_cal.xml EX-101.CAL 25227
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT drug-20210930_def.xml EX-101.DEF 211441
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT drug-20210930_lab.xml EX-101.LAB 770595
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT drug-20210930_pre.xml EX-101.PRE 317363
57 EXTRACTED XBRL INSTANCE DOCUMENT form20fa_htm.xml XML 1029548
Mailing Address 19 VESTRY STREET NEW YORK NY 10013
Business Address 19 VESTRY STREET NEW YORK NY 10013 6474072515
BRIGHT MINDS BIOSCIENCES INC. (Filer) CIK: 0001827401 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: 20-F/A | Act: 34 | File No.: 001-40997 | Film No.: 22535694
SIC: 2834 Pharmaceutical Preparations